A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer

Inclusion Criteria: * Age \>=18 years * For paclitaxel combination arms: histologically or cytologically documented adenocarcinoma of the breast with locally recurrent or metastatic disease * For docetaxel combination arms: histologically or cytologically documented adenocarcinoma of the breast with locally recurrent or metastatic disease or histologically documented advanced (Stage IV) or recurrent NSCLC * For participants with breast cancer: HER2-negative disease as defined by local clinical guidelines * Participants with NSCLC to be treated with docetaxel need to have received at least one prior anti-cancer treatment regimen in an advanced setting and to have docetaxel be considered appropriate treatment * Evaluable or measurable disease per response evaluation criteria in solid tumors (RECIST) v.1.1 * Life expectancy \>=12 weeks * Eastern cooperative oncology group (ECOG) performance status of 0 or 1 at screening * Adequate hematologic and end organ function * Use of highly effective form of contraception Exclusion Criteria: * Prior anti-cancer therapy * Prior treatment with phosphoinositide 3-kinase (PI3K) inhibitor * Known significant hypersensitivity to any components of study treatment * Grade \>=2 peripheral neuropathy * Type 1 or Type 2 diabetes * Grade \>=2 hypercholesterolemia or hypertriglyceridemia * Congenital long QT syndrome * Active congestive heart failure or ventricular arrhythmia